Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - argentum nitricum d6/atropa bella-donna d10/ceanothus americanus d4/hydrastis canadensis d6/kalium bichromicum d8/kreosotum d12/lachesis d10/mandragora e radice siccata d10/marsdenia cundurango d6/momordica balsamina d6/mucosa coli suis d8/mucosa ductus choledochi suis d8/mucosa ilei suis d8/mucosa jejuni suis d8/mucosa nasalis suis d8/mucosa oculi suis d8/mucosa oesophagi suis d8/mucosa oris suis d8/mucosa pulmonis suis d8/mucosa pylori suis d8/mucosa recti suis d8/mucosa vesicae felleae suis d8/mucosa vesicae urinariae suis d8/oxalis acetosella d6/pankreas suis d10/phosphorus d8/psychotria ipecacuanha d8/pulsatilla pratensis d6/semecarpus anacardium d6/strychnos nux-vomica d13/sulfur d8/ventriculus suis d8/veratrum album d6 - tabletės - 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg; 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 m

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

alpen pharma gmbh - cinnabaris trit. d3/hydrastis trit. d3/kalium bichromicum trit. d3/echinacea trit. d1 - tabletės - 25 mg/25 mg/25 mg/25 mg

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - aurum maculatum d4/melilotus officinalis d3/vinca minor d3/veronica officinalis d3/ammonium carbonicum d3/lemna minor d3/hydrargyrum sulfuratum rubrum d8/lobraria pulmonaria d4/hydrastis canadensis d4/phosphorus d6/kalium bichromicum d5/hydrargyrum biiodatum d8 - geriamieji lašai (tirpalas) - 5 g/5 g/5 g/5 g/5 g/5 g/10 g/10 g/10 g/10 g/10 g/5 g/100 g

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - cinnabaris trit. d3/hydrastis trit. d3/kalium bichromicum trit. d3/echinacea trit. d1 - tabletės - 25 mg/25 mg/25 mg/25 mg

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresantai - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresantai - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresantai - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - kitų antihipertenzinių vaistų - plaučių arterinės hipertenzijos (pah) gydymas, siekiant pagerinti fizinį krūvį ir simptomus pacientams, kurių funkcinė klasė yra iii pasaulinė sveikatos organizacija (pso).. veiksmingumas buvo rodomas:pirminė (idiopatinė ir šeiminė) pah;gpt antrinio sklerodermija be didelio tarpo plaučių liga;gpt, susijęs su įgimta sistemine-plaučių šuntai ir eisenmenger tai fiziologija. kai kurie patobulinimai taip pat buvo įrodyta, pacientams, sergantiems pah, kurie funkcinė klasė ii. stayveer taip pat nurodė sumažinti naujų skaitmeninių opų pacientams, sergantiems sistemine skleroze ir nuolat skaitmeninis-opa ligos.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirusiniai vaistai sisteminiam naudojimui - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 ir 5. tecovirimat siga should be used in accordance with official recommendations.